Live Breaking News & Updates on மருந்து ப்ராடக்ட்

Stay updated with breaking news from மருந்து ப்ராடக்ட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

WuXi Biologics Completed Three Acquisitions to Enhance its Global [...] | Comunicati stampa CataniaOggi


07 maggio 2021 09:02
Fonte: Adnkronos
#chimica-e-farmacia
SHANGHAI, May 7, 2021 /PRNewswire/  WuXi Biologics ( WuXi Bio ) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facility in Wuppertal, Germany, the Pfizer China ( Pfizer ) manufacturing facilities in Hangzhou, China as well as CMAB Biopharma Group ( CMAB ).
Under the acquisition agreement signed in December 2020 with Bayer, WuXi Biologics took over the operations and assets of a Drug Substance facility (MFG19) located in Wuppertal, Germany that will include 3 x 1,000L perfusion and 6 x 2,000L fed-batch capacity with independent downstream suites. Announced in March 2021, WuXi Biologics closed the acquisition of biologics drug substance and product facilities (MFG20/DP9/DP10) from Pfizer China located in Hangzhou with 2 x 2,000L single-use bioreactors that can be expanded to 4 x 2,000L. The site ....

Nordrhein Westfalen , Chris Chen , Contract Development , Biopharma Group , Manufacturing Organization , Wuxi Biologics , Pfizer China , Drug Substance , Drug Product , Hong Kong Listed , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , கிறிஸ் சென் , ஒப்பந்த வளர்ச்சி , உற்பத்தி ஆர்கநைஸேஶந் , ஃபைசர் சீனா , மருந்து பொருள் , மருந்து ப்ராடக்ட் , ஹாங் காங் பட்டியலிடப்பட்டுள்ளது ,

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021


Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers
Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r MM and ALLO-316 in advanced or metastatic clear cell renal cell carcinoma
New collaboration with Cytovia Therapeutics, Inc. to develop TALEN
®
Successful
for UCART product candidates; On track to start production of UCART product candidates in 2021 ....

New York , United States , France General , North Carolina , Simon Harnest , Margaret Gandolfo , Conor Mcgoldrick , International Financial Reporting Standards , Securities Exchange Commission , Calyxt Inc , Allogene Therapeutics Inc , American Society Of Clinical Oncology , Company At The Market , Drug Administration , American Society Of Hematology , Cytovia Therapeutics Inc , Group Share , Allogeneic Car Development Programs , Zeno Group , International Accounting Standards Board , Cellectis Sponsored Phase , Cytovia Therapeutics , Innovation Days , Multiple Myeloma , Cellectis Innovation , Cellectis Innovation Days ,